Vanda Pharmaceuticals (VNDA) 10-Q2009 Q3 Quarterly report

Filed: 4 Nov 09, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. junior Avg

New words: abstained, accident, activist, AG, agenda, alleging, ample, antitrust, arising, attention, auction, augment, bind, brain, bringing, broker, Canada, cast, clearance, complement, concentrating, constrain, consume, contest, Cosmetic, country, cycle, Dainippon, damage, delivery, diligence, disclaim, disrupting, disruption, disruptive, domestic, dramatic, Dugan, eligible, employment, enable, enhance, evolving, exacerbate, expose, external, faith, false, firm, forward, fraud, fraudulent, Halak, hand, hiring, hope, HSR, imposition, inadequate, induce, Intermezzo, introduction, joint, judicial, knowingly, length, lengthy, LLP, lost, lurasidone, mechanical, mentioned, Merck, merge, misuse, move, negative, negatively, newly, noncompliance, novelty, overhead, oversee, oversight, Pharma, Pien, pose, preclinical, proxy, Ramsay, ratification, raw, recommend, registry, request, requested, Schering, scrutiny, settlement, shut, shutdown, single, Statute, steering, strive, Sumitomo, Sustenna, thought, tightening, trademark, training, uneconomical, unforeseeable, unintended, unrelated, unsuccessful, User, voluntarily, waged, withheld

Removed: abide, Acadia, APB, approvable, assuring, bifeprunox, build, bulletin, Bush, essential, extinguished, FIN, Finally, increasing, Intermezza, Interpretation, July, larger, managerial, managing, operational, pimavanserin, pipeline, requirement, response, SAB, Shareand, Solvay, Supplementary, suspended, variety

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

VNDA similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

EXHIBIT 32.1

Certification

Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

(Subsections (a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code)

Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of section 1350, chapter 63 of title 18, United States Code), each of the undersigned officers of Vanda Pharmaceuticals Inc., (the “Company”), does hereby certify, to the best of such officer’s knowledge, that:

The Quarterly Report onForm 10-Q for the quarter ended September 30, 2009 (theForm 10-Q) of the Company fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, and the information contained in theForm 10-Q fairly presents, in all material respects, the consolidated financial condition and results of operations of the Company.


Date: November 4, 2009		/s/ Mihael H. Polymeropoulos
		Mihael H. Polymeropoulos Chairman and Chief Executive Officer (Principal Executive Officer)


Date: November 4, 2009		/s/ Stephanie R. Irish
		Stephanie R. Irish Acting Chief Financial Officer (Principal Financial and Accounting Officer)

A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission (SEC) or its staff upon request. This certification “accompanies” theForm 10-Q to which it relates, is not deemed filed with the SEC and is not to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of theForm 10-Q), irrespective of any general incorporation language contained in such filing.